Dacima has joined the EvidentIQ Group
We are pleased to announce that Dacima has joined the EvidentIQ Group, a German based end-to-end eClinical solutions company with a broad data science service portfolio and patient recruitment capabilities with locations in Germany, France and the USA. Pharmaceutical and medical device companies, clinical research institutions and universities worldwide rely on the group’s products. The transaction took place officially on July 1, 2022. You can read the press release here.
Dacima has been a leading innovator in electronic data capture (EDC) software since our founding in 2006, providing advanced, flexible EDC platform for the design and management of clinical trials, patient registries, observational studies and clinical databases. We believe the EvidentIQ group is a great fit for Dacima, as they have a similar in depth understanding of clinical research and experience in the eClinical field which complements well with Dacima.
This is an exciting announcement for us that we believe will yield important benefits for our customers, while ensuring the continuity of our business and relationships. By joining with EvidentIQ, Dacima will be able to expand and enhance our software and service offerings in the European and US markets. Dacima will operate as a standalone company in the EvidentIQ portfolio and will retain the Dacima name and brand. It will continue to be run by the same experienced team and remain headquartered in Montreal, Quebec, Canada.
Over the long-term, we believe this transaction will accelerate our ability to seize on industry growth opportunities and deliver continued product innovation and consistent, reliable operational performance. We believe this move will make Dacima even better positioned to navigate an evolving EDC industry, ensuring continuity, continued innovation in our EDC software platform and the overall long-term stability of the business.
For now, it continues to be business as usual at Dacima and you should not expect any changes in your partnership with us.
If you should have any questions, read our Q&A or contact Dacima. We would like to thank you for your continued partnership with Dacima and we look forward to continuing our relationship in the future.
Regards,
John Podoba, PhD
President & CEO
